☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
uncontrolled
Novartis' Enerzair Breezhaler Receives the EC's Approval as a Maintenance Treatment of Asthma in Adult Patients Uncontrolled with...
July 7, 2020
Novartis Terminates Clinical Development of Fevipiprant (AW039) in P-III LUSTER Studies for Patients with Uncontrolled GINA 4/5 As...
December 16, 2019
Load more...
Back to Home
Modal title
×
Modal body text goes here.